Should You Buy Keros Therapeutics Inc (KROS) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
KROS is not a good buy right now for an impatient investor. The technical setup is still bearish (negative/expanding MACD, price below pivot with weak momentum), and Intellectia has no buy signals to justify an immediate entry. Options are pricing extreme uncertainty (IV percentile 98) with mixed sentiment (put-heavy open interest but call-heavy trading today), which makes timing unfavorable unless you’re specifically trading volatility into catalysts.
Technical Analysis
Price closed at 18.12, slightly above the prior close, but still below the pivot resistance at 18.817—suggesting the stock remains in a weak/defensive zone. Momentum is bearish: MACD histogram is negative (-0.139) and expanding lower, typically consistent with downside continuation risk. RSI(6) at ~33 is near oversold territory (not a confirmed reversal signal by itself), implying sellers may be getting stretched but have not clearly reversed. Key levels: support at 18.00 then 17.495; resistance at 18.817, then 19.635 and 20.14. A convincing buy setup would more likely require reclaiming 18.817 and holding above 19.635, which is not currently in place.
